Incyte Corp
INCY
View Detailed Chart
102.690USD
+5.380+5.53%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
20.14BMarket Cap
17.03P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+5.53%
5 Days
+7.63%
1 Month
+1.35%
6 Months
+50.42%
Year to Date
+48.68%
1 Year
+53.13%
View Detailed Chart
TradingKey Stock Score of Incyte Corp
Currency: USD Updated: 2025-12-19Key Insights
Incyte Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 10/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 99.71.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Incyte Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
26
analysts
Buy
Current Rating
99.706
Target Price
+3.11%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Incyte Corp Highlights
StrengthsRisks
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 24.94% year-on-year.
Undervalued
The company’s latest PE is 17.03, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 204.09M shares, increasing 0.04% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 34.29K shares of this stock.
Incyte Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Incyte Corp Info
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Ticker SymbolINCY
CompanyIncyte Corp
CEOMeury (Bill)
Websitehttps://www.incyte.com/
FAQs
What is the current price of Incyte Corp (INCY)?
The current price of Incyte Corp (INCY) is 102.690.
What is the symbol of Incyte Corp?
The ticker symbol of Incyte Corp is INCY.
What is the 52-week high of Incyte Corp?
The 52-week high of Incyte Corp is 109.275.
What is the 52-week low of Incyte Corp?
The 52-week low of Incyte Corp is 53.560.
What is the market capitalization of Incyte Corp?
The market capitalization of Incyte Corp is 20.14B.
What is the net income of Incyte Corp?
The net income of Incyte Corp is 32.62M.
Is Incyte Corp (INCY) currently rated as Buy, Hold, or Sell?
According to analysts, Incyte Corp (INCY) has an overall rating of Buy, with a price target of 99.706.
What is the Earnings Per Share (EPS TTM) of Incyte Corp (INCY)?
The Earnings Per Share (EPS TTM) of Incyte Corp (INCY) is 6.031.
Related Instruments
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
